NeuroDerm Ltd.: NeuroDerm Announces Highly Positive Results

ND0612, a continuous 24 hours/day subcutaneous (SC) infusion?of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the primary endpoint ("ON" time without

Related Keywords

Rehovot , Hamerkaz , Israel , Germany , Osaka , Japan , United States , United Kingdom , American , Kostenloser Wertpapierhandel , C Warren Olanow , Tanabe Pharma Gmb , Enola Chen , Pharma Deutschland Gmb , Mitsubishi Chemical Group , Neuroderm Ltd , Linkedin , American Academy Of Neurology Annual Meeting , Mitsubishi Tanabe Pharma Corporation , Medicine Committee International Parkinson , Mitsubishi Pharma Europe Ltd , Movement Disorder Society Evidence , Prnewswire Neuroderm Ltd , Parkinson Foundation , Michaelj Fox Foundation , Unified Parkinson , Disease Rating Scale Part , Patient Global Impression , Clinical Global Impression , Derm Ltd , About Parkinson , Mitsubishi Chemical , Tanabe Pharma Corporation , Tanabe Pharma Gmbh , Mitsubishi Pharma Deutschland Gmbh , Mitsubishi Pharma Europe , Mitsubishi Tanabe Pharma Cooperation , Neural Transm , Choice Between Advanced Therapies , Disease Patients , Tolerability Study , Motor Fluctuations , Accessed November , American Academy , Neurology Annual Meeting , Has Parkinson , Accessed March , Rev Dis , Warren Olanow , Drug Insight , Nat Rev , Neuroderm , Nnounces , Ighly , Positive , Results , Rom , Pivotal , Hase , Groundless , Trial , Valuating , D0612 , Parkinson , Disease , Patients , Motor , Fluctuations ,